Comparative Pharmacology
Head-to-head clinical analysis: DOLOPHINE HYDROCHLORIDE versus INFUMORPH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOLOPHINE HYDROCHLORIDE versus INFUMORPH.
DOLOPHINE HYDROCHLORIDE vs INFUMORPH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methadone is a mu-opioid receptor agonist with additional NMDA receptor antagonism and serotonin/norepinephrine reuptake inhibition. It also binds to delta and kappa opioid receptors, producing analgesic and antitussive effects.
Morphine is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can interact with other opioid receptors at higher doses. It mimics endogenous endorphins by binding to opioid receptors in the CNS, causing inhibition of ascending pain pathways and altering pain perception.
Initial: 2.5-10 mg orally every 8-12 hours, titrating to effect. Maintenance: 5-20 mg orally every 8-12 hours. For severe chronic pain, dosing interval may be extended to every 12-24 hours due to long half-life. Not recommended for acute pain or as PRN analgesia.
Morphine sulfate 10-30 mg orally every 4 hours as needed; or 2.5-15 mg IV/IM/SC every 2-6 hours; or 0.5-2 mg per hour continuous IV infusion. Extended-release formulations: 15-30 mg orally every 8-12 hours.
None Documented
None Documented
Terminal elimination half-life: 15 to 60 hours (average 24-36 hours). Clinical context: Prolonged half-life due to extensive tissue binding and redistribution; accumulates with repeated dosing, requiring careful titration to avoid toxicity.
Terminal elimination half-life: 2–4 hours in healthy adults; prolonged to 4–6 hours in the elderly or those with renal impairment, leading to accumulation of active metabolites (M6G).
Primarily renal elimination of unchanged drug (approximately 50-60%) and metabolites (including the inactive metabolite 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine). Fecal excretion accounts for about 10-20%. Biliary excretion contributes minimally (<5%) to overall elimination.
Renal elimination of morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G) accounts for approximately 90% of total clearance, with <10% excreted as unchanged morphine in urine. Biliary/fecal elimination accounts for the remaining fraction (<10%).
Category C
Category C
Opioid Analgesic
Opioid Analgesic